Evidence mapPaperPMID 40697587Full record

ReviewWorld journal of diabetes2025

Exploring the link: Hemogram-derived markers in type 2 diabetes mellitus and its complications.

Gulali Aktas

Abstract readReview
In one paragraph

Review in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gulali AktasDepartment of Internal Medicine, Abant Izzet Baysal University, Bolu 14030, Türkiye. draliaktas@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia and insulin resistance, often leading to severe complications. Hemogram markers have attracted great attention from researchers for their established role in inflammatory conditions. In this respect, T2DM and its microvascular complications are characterized by high inflammatory burden. Hence, recent studies in the literature have reported an association between T2DM and hemogram-derived markers. Emerging evidence highlights the utility of hemogram-derived markers, including the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, red cell distribution width, and mean platelet volume, as potential predictors of T2DM onset and progression. These markers, readily available from routine hemogram tests, offer valuable insights into the systemic inflammation and vascular changes associated with T2DM and its complications, such as cardiovascular disease, nephropathy, and retinopathy. This review synthesizes current research on the association between hemogram-derived markers and T2DM, emphasizing their prognostic value in predicting disease severity and complications. We also explore the underlying pathophysiological mechanisms linking these markers to inflammation and metabolic dysfunction. The findings suggest that hemogram-derived markers could serve as cost-effective, non-invasive tools for risk stratification and early intervention in T2DM management. Future research should focus on standardizing reference ranges and validating these markers in diverse populations to enhance their clinical utility.

Indexed as

Hemogram markersInflammationMacrovascular complicationsMicrovascular complicationsType 2 diabetes mellitus

Identifiers

PMID40697587
PMCPMC12278093

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.